To evaluate the neuroprotective activity of Gentisic acid in PD. The study was conducted on swiss albinFo mice (20-25 g) & wistar rats (200-250 g).

Three behavioural models namely, Haloperidol induced catalepsy, Reserpine antagonism and Haloperidol induce orofacial dyskinesia were employed in this study, Swiss Albino mice (20-25 g) were used in first two models while Wistar rats (200-250 g) used in last one model. There are five group (n=6) in each animal model. Various behavior activity/parameter (cataleptic behavior, horizontal movements, rearing & grooming frequencies and Dyskinesia activity like vacuous chewing & tongue protrusion) in different animal models were used to evaluate the anti-Parkinson's activity of Gentisic acid.

Gentisic acid showed a significant (P<0.01) reduction in the duration of cataleptic behavior dose dependently when compared to haloperidol control group. Gentisic acid shows dose dependant increase in the frequency of horizontal movement and rearing behavior when compared to the Reserpine control group. But, the effect of Gentisic acid on the frequency of grooming behavior was found to be insignificant. Gentisic acid (80 mg/kg) showed a significant (P<0.05) decrease in the frequency of vacuous chewing & tongue protrusion but the other dose tested were found to be insignificant in this respect.

Results shows that the Gentisic acid produced dose dependent neuroprotective activity in different animal models of PD.